- Home
- ARR vs ZLAB Comparison
ARR vs ZLAB Comparison
Compare ARR & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARR | ZLAB |
|---|---|---|
| Founded | 2008 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | ARR | ZLAB |
|---|---|---|
| Price | $17.49 | $20.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $18.00 | ★ $49.60 |
| AVG Volume (30 Days) | ★ 2.8M | 692.2K |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 16.62% | N/A |
| EPS Growth | N/A | ★ 38.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $460,156,000.00 |
| Revenue This Year | N/A | $9.75 |
| Revenue Next Year | N/A | $26.03 |
| P/E Ratio | $27.18 | ★ N/A |
| Revenue Growth | N/A | ★ 15.33 |
| 52 Week Low | $13.66 | $15.96 |
| 52 Week High | $19.31 | $44.34 |
Technical Indicators
Market Signals| Indicator | ARR | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 56.92 | 62.28 |
| Support Level | $17.20 | $16.88 |
| Resistance Level | $17.71 | $27.23 |
| Average True Range (ATR) | 0.47 | 0.74 |
| MACD | 0.18 | 0.33 |
| Stochastic Oscillator | 94.34 | 78.48 |
Price Performance
Historical ComparisonAbout ARR ARMOUR Residential REIT Inc.
ARMOUR Residential REIT Inc operate in the U.S. and invest in fixed rate residential, adjustable rate and hybrid adjustable rate residential MBS issued or guaranteed by U.S. GSEs or guaranteed by Ginnie Mae. It also invest in U.S. Treasury Securities and money market instruments.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.